Metaproterenol (Alupent) metered dose inhaler in children 5-12 years of age.
This multiclinic study was performed to evaluate the safety and efficacy of metaproterenol sulfate (Alupent) metered dose inhaler in children with asthma ages 5 to 12 years. A total of 268 children completed this study according to the protocol, having received either metaproterenol or placebo for 30 consecutive days. Full spirometric testing was done pre- and postdose on Days 1 and 30 for a total duration of 6 hours on each day. The results showed that metaproterenol was consistently superior to placebo in all pulmonary function parameters measured on Days 1 and 30. This difference was statistically significant for peak values and areas under the curves for both FEV1 and FEF25-75%. There were no significant side effects noted. We conclude that metaproterenol metered dose inhaler is safe and effective in the treatment of asthma in children ages 5 to 12 years.
W W
WW
Storms
C W
CW
Bierman
H
H
Chai
R J
RJ
Dockhorn
P
P
Eggleston
E F
EF
Ellis
C
C
Feldman
J N
JN
Fink
M P
MP
Hemstreet
W T
WT
Kniker
D000280:Administration, Inhalation; D001249:Asthma / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D009921:Metaproterenol / Q000008:administration & dosage* / Q000009:adverse effects; D009330:Nebulizers and Vaporizers; D013997:Time Factors
D009921:Metaproterenol